Damora Therapeutics (DMRA) Stock Forecast & Price Target

DMRA$21.60-0.45 -2.04%
BiotechnologyGrowth Stock
Compare
Market cap$1.34BEnterprise value$988.58MRevenue (TTM)$0Market position—

Score

70
Bullish
Value
58
Quality
52
Growth
100

Damora Therapeutics, Inc. price target

DMRA
Low$40.00
Average$52.50
High$60.00
Upside vs current price+143.1%

The average target of $52.50 is +143.1% versus the current DMRA price of $21.60.

Damora Therapeutics, Inc. analyst ratings

RatingAnalysts
Strong buy1
Buy9
Hold0
Sell0
Strong sell0
ConsensusBuy

10 analysts cover DMRA.

Damora Therapeutics, Inc. EPS and revenue estimates

The estimate table for the Damora Therapeutics, Inc. keeps 2026 EPS $-2.00, 2027 EPS $-2.15, and years with fewer than three analysts are not filled in.

Fiscal yearEPS estimateRevenue estimate
2026$-2.00—
2027$-2.15—

Is Damora Therapeutics, Inc. a buy or sell?

Of the 10 analysts covering Damora Therapeutics, Inc., 10 rate it a buy (1 strong buy and 9 buy), 0 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).

The DMRA consensus label is Buy, beside 10 buy-side ratings and 0 sell-side ratings.

The average target of $52.50 implies +143.1% versus the current price of $21.60.

the Damora Therapeutics, Inc. closes with 10 buy-side ratings and 0 on the sell side. The headcount is Buy.

Reading the Damora Therapeutics, Inc. forecast

Between the DMRA low of $40.00 and the high of $60.00, the average target is $52.50.

From today's $21.60 print, the DMRA average target is +143.1% away.

Most of the DMRA coverage agrees: 10 of 10 analysts are on the buy side, 0 are at hold, and 0 are on the sell side, and the published consensus is Buy.

Earnings estimates for DMRA are falling: 2026 $-2.00, then 2027 $-2.15.

DMRA coverage is thin at 10 analysts, and one revision moves the average.

Damora Therapeutics, Inc. forecast questions

What is the DMRA price target?

The published range for DMRA is $40.00 to $60.00, with an average of $52.50. That average is +143.1% versus the current price of $21.60.

Is Damora Therapeutics, Inc. a buy or sell?

Of the 10 analysts covering Damora Therapeutics, Inc., 10 rate it a buy, 0 rate it a hold, and 0 rate it a sell. The consensus is Buy, which for DMRA is 10 on the buy side, 0 at hold, and 0 on the sell side.

What is the EPS estimate for Damora Therapeutics, Inc.?

Analyst EPS estimates for Damora Therapeutics, Inc.: 2026 $-2.00, 2027 $-2.15.

What is the revenue estimate for Damora Therapeutics, Inc.?

No revenue estimate with at least 3 analysts is on file for Damora Therapeutics, Inc..

How many analysts cover DMRA?

10 analysts cover DMRA. Their consensus on DMRA is Buy, across those 10.

DMRA price $21.60 -0.45 -2.04%

Insights · Forecast · Financials · Learn

Stocklytics home · Screener